Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, t
Veru to Present at Three Upcoming Healthcare Investment Conferences
08:30am, Wednesday, 08'th Sep 2021
MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, t
Why Veru Stock Vaulted Higher Today
03:44pm, Thursday, 02'nd Sep 2021
An analyst raised his price target for the stock.
Why Veru Stock Blasted Higher on Friday
04:25pm, Friday, 27'th Aug 2021
An analyst argues that the company has far more value than many realize.
Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript
05:10pm, Thursday, 12'th Aug 2021
Veru, Inc. (VERU) CEO Mitchell Steiner on Q3 2021 Results - Earnings Call Transcript
Veru Stock Gains After Q3 Result Tops Estimates
01:04pm, Thursday, 12'th Aug 2021
Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2 prescription net revenues climbed 150%
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
10:06am, Thursday, 12'th Aug 2021
Veru Inc. (VERU) delivered earnings and revenue surprises of 50.00% and 26.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter
06:30am, Thursday, 12'th Aug 2021
--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs—
MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, t
--Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resis
--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021--
-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40%
-- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study
Veru to Present at the Jefferies Virtual Healthcare Conference
08:30am, Tuesday, 25'th May 2021
MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod
-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targe
